11/28
02:41 pm
acet
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Neutral
Report
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/28
02:23 pm
acet
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
11/19
06:02 am
acet
Adicet Bio (NASDAQ:ACET) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Adicet Bio (NASDAQ:ACET) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..
11/7
08:07 am
acet
Adicet Bio (NASDAQ:ACET) had its price target raised by analysts at HC Wainwright from $4.00 to $9.00. They now have a "buy" rating on the stock.
Medium
Report
Adicet Bio (NASDAQ:ACET) had its price target raised by analysts at HC Wainwright from $4.00 to $9.00. They now have a "buy" rating on the stock.
11/6
01:21 pm
acet
Adicet Bio (NASDAQ:ACET) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Low
Report
Adicet Bio (NASDAQ:ACET) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
11/5
04:01 pm
acet
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Low
Report
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
10/31
04:59 pm
acet
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/30
12:24 pm
acet
Adicet Bio (NASDAQ:ACET) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Adicet Bio (NASDAQ:ACET) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/28
07:00 am
acet
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Medium
Report
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
10/16
07:00 am
acet
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
Medium
Report
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
10/8
08:20 am
acet
Adicet Bio (NASDAQ:ACET) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Adicet Bio (NASDAQ:ACET) had its "buy" rating reaffirmed by analysts at Guggenheim.
10/7
12:38 pm
acet
Adicet Bio, Inc. - Special Call [Seeking Alpha]
Low
Report
Adicet Bio, Inc. - Special Call [Seeking Alpha]
10/7
07:33 am
acet
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering [Yahoo! Finance]
High
Report
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering [Yahoo! Finance]
10/7
07:16 am
acet
Adicet Bio launches $80M securities offering [Seeking Alpha]
High
Report
Adicet Bio launches $80M securities offering [Seeking Alpha]
10/7
07:01 am
acet
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
High
Report
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
10/7
06:53 am
acet
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]
High
Report
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]
10/7
06:45 am
acet
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
High
Report
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
10/3
02:47 pm
acet
Adicet Bio (NASDAQ:ACET) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Adicet Bio (NASDAQ:ACET) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
9/30
04:27 pm
acet
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
9/19
08:47 am
acet
Adicet Bio (NASDAQ:ACET) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $7.00 price target on the stock.
Medium
Report
Adicet Bio (NASDAQ:ACET) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $7.00 price target on the stock.